Azenta (NASDAQ:AZTA – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its competitors? We will compare Azenta to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Volatility and Risk
Azenta has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Azenta’s competitors have a beta of 0.93, indicating that their average share price is 7% less volatile than the S&P 500.
Profitability
This table compares Azenta and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -26.86% | 1.41% | 1.15% |
| Azenta Competitors | -487.63% | 79.17% | -12.95% |
Dividends
Azenta pays an annual dividend of $0.10 per share and has a dividend yield of 0.2%. Azenta pays out -2.8% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.1% and pay out 45.1% of their earnings in the form of a dividend.
Analyst Recommendations
This is a summary of current ratings and target prices for Azenta and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| Azenta Competitors | 957 | 3193 | 5531 | 179 | 2.50 |
Azenta currently has a consensus price target of $47.60, indicating a potential upside of 4.93%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.96%. Given Azenta’s higher possible upside, equities analysts plainly believe Azenta is more favorable than its competitors.
Institutional & Insider Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Azenta and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Azenta | $621.70 million | -$166.99 million | -12.53 |
| Azenta Competitors | $2.33 billion | $55.11 billion | -7.63 |
Azenta’s competitors have higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Azenta competitors beat Azenta on 8 of the 15 factors compared.
About Azenta
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
